HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Intensity Therapeutics (NASDAQ:INTS) with a Buy and raises the price target from $5 to $7.